Table 1. No evidence of molecular evolution during effective cART.

PID, participant ID.

PID	ART duration (years)	Source	Total SGSs recovered	Hypermutants	Total SGS hypermutants	Average pairwise difference (%)	Mean root-to-tip distance
AVBIO2-15	0.0	Plasma	17	0	17	0.2	0.001
	11.7	Plasma	21	0	21	0.11	0.001
	14.8	PBMC	17	0	17	0.18	0.001
	15.3	PBMC	14	1	13	0.22	0.001
	15.3	Colon	19	1	18	0.29	0.001
	15.3	Ileum	12	0	12	0.24	0.001
AVBIO2-04	0.0	PBMC	30	2	28	0.12	0.001
	20	PBMC	6	1	5	0.0005	0.0005
	2.1	Plasma	4	0	4	0.0004	0.0002
	6.8	PBMC	17	1	16	0.1	0.001
	15.9	PBMC	14	6	8	0.04	0.0002
	18.9	Ileum and colon	41	31	10	0.08	0.0004
HAMB-1	6.0	PBMC	20	1	19	0.28	0.0015
	6.2	PBMC	29	5	24	0.34	0.0016
	6.6	PBMC	30	5	25	0.29	0.0018
	7.8	PBMC	43	18	25	0.26	0.0015
	8.0	Spleen	38	10	28	0.26	0.0019
	8.0	Lymph node	30	4	26	0.32	0.0018
	8.0	Kidney and lung	8	2	6	0.46	0.0024
	8.0	Testes	2	1	1	–	–
	8.0	Colon	5	5	0	–	–
	8.0	Ileum	23	2	21	0.25	0.0014
	8.0	Jejunum	12	2	10	0.17	0.0009
HAMB-2	19.1 + 19.2	PBMC	46	6	40	1.5	0.009
	22.7	Spleen	21	0	22	1.7	0.01
	22.7	Lymph node-1	20	1	19	1.6	0.011
	22.7	Lymph node-2	30	3	27	1.8	0.011
	22.7	Lung	33	1	32	1.8	0.011
	22.7	Testes	5	0	5	1.6	0.009
		Frontal
	22.7	+Occipital lobe	6	0	6	1.2	0.007
AVBIO2-35	0.0	Plasma	23	0	23	1	0.006
	0.0	PBMC	4	0	4	1.2	0.007
	8.3	Plasma	45	0	45	1	0.021
	19.4	PBMC	20	0	20	1.4	0.017
	19.7	Plasma	9	0	9	0.9	0.021
	19.7	PBMC	33	2	31	1.5	0.016
	19.7	Colon	22	2	20	1.1	0.02
	19.7	Ileum	14	0	14	1.1	0.021
AVBIO2-37	0.0	Plasma	17	0	17	1.7	0.01
	0.0	PBMC	20	0	20	1.8	0.012
	3.3	Plasma	28	0	28	1.1	0.026
	19.4	Plasma	17	0	17	1.6	0.015
	19.4	PBMC	27	1	26	2.5	0.018
	19.7	Colon	19	1	18	2.7	0.02
	19.7	Ileum	30	1	29	2.6	0.019
	19.7	Plasma	17	0	17	1.6	0.015
	19.7	PBMC	26	0	26	2.5	0.017
	20.0	Plasma	39	4	35	1.3	0.014